Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been given a consensus rating of “Hold” by the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.1250.

A number of research firms have commented on REPL. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research report on Friday, April 10th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Weiss Ratings downgraded Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a report on Tuesday, June 30th. Finally, Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $11.58 on Friday. The company has a market capitalization of $972.03 million, a P/E ratio of -3.43 and a beta of 0.86. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The company has a 50 day simple moving average of $7.16 and a 200-day simple moving average of $7.35. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, equities research analysts predict that Replimune Group will post -2.25 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Replimune Group

Institutional investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new stake in Replimune Group in the first quarter valued at approximately $921,000. Essential Partners LLC boosted its position in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the period. Bank of America Corp DE boosted its position in shares of Replimune Group by 17.7% during the first quarter. Bank of America Corp DE now owns 253,449 shares of the company’s stock worth $1,939,000 after buying an additional 38,119 shares during the period. Readystate Asset Management LP acquired a new stake in shares of Replimune Group in the first quarter valued at $1,059,000. Finally, EcoR1 Capital LLC acquired a new stake in shares of Replimune Group in the first quarter valued at $7,650,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.